Neuroprotection in ischemic stroke: What does the future hold?

Expert Review of Neurotherapeutics

Volumn 15, Issue 3, 2015, Pages 227-229

  Korczyn, Amos D ^a   Brainin, Michael ^b   Guekht, Alla ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b DANUBE UNIVERSITY KREMS   (Austria)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

actovegin; cerebral ischemia; neuroprotection; stroke; therapy; vascular dementia

Indexed keywords

ACTOVEGIN; CEREBROLYSIN; CYTOKINE; NEUROPROTECTIVE AGENT;

ANGIOGENESIS; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN ISCHEMIA; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; HUMAN; INCIDENCE; MEMORY DISORDER; MENTAL CAPACITY; MULTIINFARCT DEMENTIA; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; PATHOPHYSIOLOGY; PILOT STUDY; PROSPECTIVE STUDY; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL BEHAVIOR; STROKE PATIENT; TRANSCRANIAL MAGNETIC STIMULATION; VASCULAR COGNITIVE IMPAIRMENT; WHITE MATTER LESION; STROKE;

BRAIN ISCHEMIA; HUMANS; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84923351230     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1014806     Document Type: Review

References (24)

1. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012;19(1):155-62
2. Kovacs GG, Milenkovic I, Wohrer A, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013;126(3):365-84
3. Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci 2012;322(1-2):2-10
4. Korczyn AD. Mixed dementia-the most common cause of dementia. Ann N Y Acad Sci 2002;977:129-34
5. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Inflammation in ischemic stroke subtypes. Curr Pharm Des 2012;18:4289-310
6. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000;31:2325-9
7. Ihara M, Kalaria RN. Understanding and preventing the development of post-stroke dementia. Expert Rev Neurother 2014;14:1067-77
8. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357(6):562-71
9. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40(12):e647-56
10. Machicao F, Muresanu DF, Hundsberger H, et al. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci 2012;322(1-2):222-7
11. Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med 2011;13(4):266-74
12. Ubhi K, Rockenstein E, Vazquez-Roque R, et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. J Neurosci Res 2013;91(2):167-77
13. Heiss WD, Brainin M, Bornstein NM, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012;43(3):630-6
14. Efficacy and safety of actovegin in post-stroke cognitive impairment (PSCI) (ARTEMIDA). Available from: https:// clinicaltrials.gov/ct2/show/NCT01582854
15. Nagel S, Papadakis M, Chen R, et al. Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2011;31(1):132-43
16. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003;17(3):152-7
17. Pradillo JM, Denes A, Greenhalgh AD, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 2012;32(9):1810-19
18. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76(10):1366-72
19. Wu TC, Grotta JC. Hypothermia for acute ischaemic stroke. Lancet Neurol 2013;12(3):275-84
20. Kasner SE, Rose DZ, Skokan A, et al. Transcranial laser therapy and infarct volume. Stroke 2013;44(7):2025-7
21. Spector A, Orrell M, Hall L. Systematic review of neuropsychological outcomes in dementia from cognition-based psychological interventions. Dement Geriatr Cogn Disord 2012;34(3-4):244-55
22. Hao Z, Wang D, Zeng Y, Liu M. Repetitive transcranial magnetic stimulation for improving function after stroke. Cochrane Database Syst Rev 2013;5: CD008862
23. Janssen H, Bernhardt J, Collier JM, et al. An enriched environment improves sensorimotor function post-ischemic stroke. Neurorehabil Neural Repair 2010;24(9):802-13
24. Janssen H, Ada L, Bernhardt J, et al. An enriched environment increases activity in stroke patients undergoing rehabilitation in a mixed rehabilitation unit: a pilot non-randomized controlled trial. Disabil Rehabil 2014;36(3):255-62